Pulmonary Stents - Global Strategic Business Report 2026

The global market for Pulmonary Stents was valued at US$223.5 Million in 2025 and is projected to reach US$318.6 Million by 2032, growing at a CAGR of 5.2% from 2025 to 2032. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.

Global Pulmonary Stents Market - Key Trends & Drivers SummarizedWhy Are Pulmonary Stents Becoming Essential in Respiratory Medicine?

Pulmonary stents play a crucial role in managing airway obstruction caused by conditions such as tracheobronchial stenosis, lung cancer, chronic obstructive pulmonary disease (COPD), and post-surgical complications. These stents help maintain airway patency, allowing patients to breathe more easily and improving overall quality of life. As the prevalence of respiratory disorders continues to rise due to environmental pollution, smoking, and aging populations, the demand for pulmonary stents has grown significantly. Unlike invasive surgical procedures, stent placement via bronchoscopy offers a minimally invasive solution, reducing patient recovery time and hospital stays. The increasing preference for non-surgical interventions in respiratory care has driven advancements in pulmonary stent technology, making them more effective, durable, and biocompatible. Healthcare providers are increasingly incorporating pulmonary stents into treatment protocols to manage complex airway diseases, leading to expanded adoption across hospitals and specialty clinics worldwide.

How Are Technological Advancements Improving Pulmonary Stent Performance?

Recent innovations in pulmonary stent design and materials have significantly enhanced their clinical efficacy and patient outcomes. Traditional metal and silicone stents have been refined to minimize migration risks and improve long-term stability within the airways. The introduction of self-expanding stents, which adapt to airway contours and reduce the need for frequent repositioning, has improved procedural success rates. Furthermore, drug-eluting pulmonary stents, coated with anti-inflammatory or anti-proliferative agents, are being developed to prevent restenosis and reduce the likelihood of repeat interventions. Bioresorbable stents, which gradually dissolve over time, are emerging as a promising alternative for temporary airway support, eliminating the need for stent removal procedures. Enhanced imaging technologies such as high-resolution CT scans and guided bronchoscopy have also improved the precision of stent placement, reducing complications and optimizing treatment outcomes. As research continues to focus on improving stent flexibility, biocompatibility, and long-term efficacy, the next generation of pulmonary stents is expected to set new standards in respiratory medicine.

What Factors Are Driving the Adoption of Pulmonary Stents?

The increasing prevalence of lung diseases, coupled with rising awareness about minimally invasive treatment options, has fueled the demand for pulmonary stents. Patients and healthcare providers are favoring bronchoscopic stenting over traditional open surgeries due to lower risks, faster recovery times, and improved patient comfort. The rising incidence of lung cancer, particularly in aging populations, has further accelerated the need for airway management solutions, with pulmonary stents being widely used for palliative care in advanced-stage cancer patients. Additionally, the growing number of COPD cases worldwide, driven by air pollution and smoking habits, has led to increased stent placements to manage airway obstruction effectively. Technological advancements in stent manufacturing, such as hybrid designs that combine the benefits of metal and silicone, are also contributing to market growth by offering enhanced durability and functionality. The availability of reimbursement policies for pulmonary interventions in many developed countries is further encouraging hospitals and specialty clinics to adopt these devices for airway management.

What Are the Key Drivers Fueling Growth in the Pulmonary Stents Market?

The growth in the global pulmonary stents market is driven by several key factors, including the rising incidence of chronic respiratory diseases, advancements in stent design and materials, and the increasing adoption of minimally invasive airway management techniques. The expansion of healthcare infrastructure, particularly in emerging markets, is improving access to advanced respiratory treatments, boosting demand for pulmonary stents. The integration of AI-powered imaging and robotic-assisted bronchoscopy is also enhancing procedural accuracy, making stent placement more effective and reducing complication rates. Furthermore, the growing investment in respiratory care by healthcare providers, research institutions, and medical device manufacturers is accelerating innovation in pulmonary stent technology. Regulatory approvals for next-generation stents, along with increasing collaborations between medical device companies and healthcare organizations, are further driving market expansion. As the demand for effective airway management solutions continues to grow, the pulmonary stents market is poised for sustained development, with ongoing advancements shaping the future of respiratory care.

Report Scope

The report analyzes the Pulmonary Stents market, presented in terms of market value (US$). The analysis covers the key segments and geographic regions outlined below:

• Segments: Product (Self-expandable Stents, Balloon-expandable Stents); Material (Metal, Silicon, Hybrid); Type (Tracheobronchial Stents, Laryngeal Stents).
• Geographic Regions/Countries: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Key Insights:

• Market Growth: Understand the significant growth trajectory of the Self-expandable Stents segment, which is expected to reach US$215.6 Million by 2032 with a CAGR of a 6.1%. The Balloon-expandable Stents segment is also set to grow at 3.5% CAGR over the analysis period.
• Regional Analysis: Gain insights into the U.S. market, valued at $65.4 Million in 2025, and China, forecasted to grow at an impressive 5% CAGR to reach $56.7 Million by 2032. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

• Detailed Market Analysis: Access a thorough analysis of the Global Pulmonary Stents Market, covering all major geographic regions and market segments.
• Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
• Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Pulmonary Stents Market.
• Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

• How is the Global Pulmonary Stents Market expected to evolve by 2032?
• What are the main drivers and restraints affecting the market?
• Which market segments will grow the most over the forecast period?
• How will market shares for different regions and segments change by 2032?
• Who are the leading players in the market, and what are their prospects?

Report Features:

• Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2025 to 2032.
• In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
• Company Profiles: Coverage of players such as Abbott, B. Braun Melsungen AG, Bayer AG, Bess Medizintechnik GmbH, Biosensors International Group, Ltd. and more.
• Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Some of the companies featured in this Pulmonary Stents market report include:

• Abbott
• B. Braun Melsungen AG
• Bayer AG
• Bess Medizintechnik GmbH
• Biosensors International Group, Ltd.
• BIOTRONIK SE & Co. KG
• Boston Scientific Corporation
• Cardinal Health, Inc. (Cordis)
• Cook Group
• E. Benson Hood Laboratories, Inc.
• EFER ENDOSCOPY
• ENDO-FLEX GmbH
• GlaxoSmithKline plc
• Johnson & Johnson Services, Inc.
• Lepu Medical Technology
• M.I. Tech
• Medtronic plc
• Merit Medical Systems, Inc.
• MicroPort Scientific Corporation
• Micro-Tech (Nanjing) Co., Ltd.

What Sets This Report Apart From Others?

• Grounded in Domain Expert Perspectives: Incorporates perspectives emerging from domain experts across industry, enterprise and academia, adding context beyond conventional published research.
• Captures Early Market Signals: Tracks shifts emerging through expert conversations, company activity and market-relevant discussions before they are fully reflected in traditional secondary research.
• Draws From a Broad, Validated Intelligence Base: Brings together insights from conference sessions, keynotes, panel discussions, blogs, corporate disclosures, annual reports, institutional publications and other validated sources.
• Connects Signals With Strategic Market Direction: Synthesizes these perspectives to identify where the market is moving, what is driving that movement and which developments are likely to matter most for strategy.
• Provides In-Depth Company Intelligence: Extends beyond market-level analysis to examine the companies participating in and shaping the competitive environment.
• Market Share Is Examined Where It Matters: A single global market share figure rarely tells the full story. Competitive structures can vary significantly across geographies. Where analytically relevant, our reports extend market share analysis into major regions with the level of detail tailored to the structure and dynamics of each market.